Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb strengthens clinical development capabilities

Bristol-Myers Squibb strengthens clinical development capabilities

15th June 2010

Bristol-Myers Squibb is to ally with clinical development services providers Parexel and Icon in a bid to improve the efficiency of its clinical research processes.

Responding to the large volume of clinical development work set to be undertaken by the firm in the coming months, Bristol-Myers Squibb has signed agreements with the two companies to provide joint strategic, operational and capability support.

This deal will see Parexel and Icon support the biopharmaceutical firm’s global research activities for its full development pipeline over the next three years.

Brian Daniels, senior vice-president of global development at Bristol-Myers Squibb, said the deal would ultimately enhance its ability to bring new medicines to patient populations.

He added: “These partnerships will increase the operational capability of our clinical development organisation and support our industry-leading position in productivity and innovation.”

Earlier this week, Bristol-Myers Squibb revealed that it has halted a clinical trial of apixaban early after the atrial fibrillation drug demonstrated its efficacy ahead of schedule.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.